CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression

PLoS Pathogens

Volumn 10, Issue 9, 2014, Pages

  Viganò, Selena ^a   Banga, Riddhima ^a   Bellanger, Florence ^a   Pellaton, Céline ^a   Farina, Alex ^a   Comte, Denis ^a   Harari, Alexandre ^a   Perreau, Matthieu ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD160 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; CD160 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CD8 T CELL FUNCTIONAL IMPAIRMENT; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION ASSAY; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; VIROLOGY; WESTERN BLOTTING;

ANTIGENS, CD; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HEPACIVIRUS; HEPATITIS C; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC;

EID: 84907588618     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004380     Document Type: Article

References (43)

1. Lenschow DJ, Bluestone JA, (1993) T cell co-stimulation and in vivo tolerance. Curr Opin Immunol 5: 747–752.
2. Vigano S, Perreau M, Pantaleo G, Harari A, (2012) Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012: 485781.
3. Leibson PJ, (2004) The regulation of lymphocyte activation by inhibitory receptors. Curr Opin Immunol 16: 328–336.
4. Chen L, (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nature reviews Immunology 4: 336–347.
5. Cai G, Freeman GJ, (2009) The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 229: 244–258.
6. Cannons JL, Tangye SG, Schwartzberg PL, (2011) SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol 29: 665–705.
7. Carreno BM, Collins M, (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20: 29–53.
8. Khaitan A, Unutmaz D, (2011) Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 8: 4–11.
9. Lenschow DJ, Walunas TL, Bluestone JA, (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233–258.
10. Watts TH, (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23–68.
11. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.
12. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, et al. (2006) PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203: 2281–2292.
13. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, et al. (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12: 1198–1202.
14. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, et al. (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120: 4546–4557.
15. Wherry EJ, Ahmed R, (2004) Memory CD8 T-cell differentiation during viral infection. J Virol 78: 5535–5545.
16. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R, (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911–4927.
17. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, et al. (2011) Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood 117: 4805–4815.
18. Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP, et al. (2012) CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog 8: e1002840.
19. Vigano S, Bellutti Enders F, Miconnet I, Cellerai C, Savoye AL, et al. (2013) Rapid Perturbation in Viremia Levels Drives Increases in Functional Avidity of HIV-specific CD8 T Cells. PLoS Pathog 9: e1003423.
20. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682–687.
21. Makedonas G, Hutnick N, Haney D, Amick AC, Gardner J, et al. (2010) Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog 6: e1000798.
22. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA, (2013) Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells. Front Immunol 4: 455.
23. Harari A, Enders FB, Cellerai C, Bart PA, Pantaleo G, (2009) Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J Virol 83: 2862–2871.
24. Cellerai C, Perreau M, Rozot V, Enders FB, Pantaleo G, et al. (2010) Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression. Journal of virology 84: 3868–3878.
25. Speiser DE, Colonna M, Ayyoub M, Cella M, Pittet MJ, et al. (2001) The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J Immunol 167: 6165–6170.
26. Petrovas C, Chaon B, Ambrozak DR, Price DA, Melenhorst JJ, et al. (2009) Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol 183: 1120–1132.
27. Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, et al. (1996) Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 8: 773–780.
28. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, et al. (2010) Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 6: e1000947.
29. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, et al. (2008) CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 9: 176–185.
30. Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, et al. (1999) Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J Immunol 162: 1223–1226.
31. Barakonyi A, Rabot M, Marie-Cardine A, Aguerre-Girr M, Polgar B, et al. (2004) Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J Immunol 173: 5349–5354.
32. Le Bouteiller P, Tabiasco J, Polgar B, Kozma N, Giustiniani J, et al. (2011) CD160: a unique activating NK cell receptor. Immunol Lett 138: 93–96.
33. Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, et al. (1998) Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol 161: 2780–2790.
34. Giustiniani J, Bensussan A, Marie-Cardine A, (2009) Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation. J Immunol 182: 63–71.
35. Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, et al. (2011) A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med 208: 973–986.
36. del Rio ML, Lucas CL, Buhler L, Rayat G, Rodriguez-Barbosa JI, (2010) HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. Journal of leukocyte biology 87: 223–235.
37. Rabot M, El Costa H, Polgar B, Marie-Cardine A, Aguerre-Girr M, et al. (2007) CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int Immunol 19: 401–409.
38. Liu FT, Giustiniani J, Farren T, Jia L, Bensussan A, et al. (2010) CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood 115: 3079–3088.
39. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, et al. (2007) Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A 104: 16233–16238.
40. Perreau M, Mennechet F, Serratrice N, Glasgow JN, Curiel DT, et al. (2007) Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 81: 3272–3284.
41. Perreau M, Welles HC, Harari A, Hall O, Martin R, et al. (2011) DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell responses in Intestinal Mucosa. Journal of virology 85 (19) 9854–62.
42. Perreau M, Welles HC, Harari A, Calandra T, Roger T, et al. (2011) Modulation of human memory T-cell function by different antigen-presenting cells. Eur J Immunol 42 (3) 799–802.
43. Roederer M, Nozzi JL, Nason MC, (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry Part A: the journal of the International Society for Analytical Cytology 79: 167–174.